IFP Advisors’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $13.2K | Sell |
58
-710
| -92% | -$126K | ﹤0.01% | 3227 |
|
|
2026
Q1 | $132K | Buy |
768
+656
| +586% | +$122K | ﹤0.01% | 1648 |
|
|
2025
Q4 | $22.3K | Sell |
112
-4
| -3% | -$726 | ﹤0.01% | 2676 |
|
|
2025
Q3 | $18.1K | Buy |
116
+112
| +2,800% | +$17.8K | ﹤0.01% | 2626 |
|
|
2025
Q2 | $41.3K | Sell |
4
-219
| -98% | -$29.2K | ﹤0.01% | 2153 |
|
|
2025
Q1 | $36.2K | Buy |
223
+4
| +2% | +$671 | ﹤0.01% | 2047 |
|
|
2024
Q4 | $43.7K | Buy |
219
+9
| +4% | +$1.73K | ﹤0.01% | 1887 |
|
|
2024
Q3 | $41.4K | Buy |
210
+152
| +262% | +$31.6K | ﹤0.01% | 1817 |
|
|
2024
Q2 | $12K | Buy |
58
+51
| +729% | +$11.6K | ﹤0.01% | 2281 |
|
|
2024
Q1 | $1.9K | Buy |
7
+5
| +250% | +$1.19K | ﹤0.01% | 2712 |
|
|
2023
Q4 | $473 | Sell |
2
-54
| -96% | -$10.6K | ﹤0.01% | 2880 |
|
|
2023
Q3 | $11K | Buy |
56
+43
| +331% | +$8.83K | ﹤0.01% | 2219 |
|
|
2023
Q2 | $2.73K | Buy |
13
+7
| +117% | +$1.39K | ﹤0.01% | 2775 |
|
|
2023
Q1 | $649 | Sell |
6
-351
| -98% | -$79.5K | ﹤0.01% | 3153 |
|
|
2022
Q4 | $48K | Sell |
357
-2,405
| -87% | -$525K | ﹤0.01% | 2272 |
|
|
2022
Q3 | $329K | Buy |
2,762
+96
| +4% | +$20.7K | 0.01% | 1143 |
|
|
2022
Q2 | $314K | Hold |
2,666
| – | – | 0.01% | 1045 |
|
|
2022
Q1 | $314K | Buy |
2,666
+2,162
| +429% | +$667K | 0.01% | 1045 |
|
|
2021
Q4 | $190K | Sell |
504
-136
| -21% | -$52.8K | ﹤0.01% | 968 |
|
|
2021
Q3 | $264K | Sell |
640
-33
| -5% | -$13.7K | 0.01% | 824 |
|
|
2021
Q2 | $247K | Buy |
673
+21
| +3% | +$7.01K | 0.01% | 801 |
|
|
2021
Q1 | $192K | Buy |
652
+40
| +7% | +$11.1K | ﹤0.01% | 855 |
|
|
2020
Q4 | $150K | Buy |
612
+250
| +69% | +$59.5K | 0.01% | 931 |
|
|
2020
Q3 | $80K | Sell |
362
-25
| -6% | -$5.19K | ﹤0.01% | 1093 |
|
|
2020
Q2 | $65K | Buy |
387
+6
| +2% | +$958 | 0.01% | 1093 |
|
|
2020
Q1 | $49K | Buy |
381
+105
| +38% | +$15.7K | ﹤0.01% | 1124 |
|
|
2019
Q4 | $41K | Buy |
276
+31
| +13% | +$4.29K | ﹤0.01% | 1337 |
|
|
2019
Q3 | $31K | Buy |
+245
| New | +$32.8K | ﹤0.01% | 1574 |
|
|
2019
Q1 | – | Sell |
-154
| Closed | -$17K | – | 2552 |
|
|
2018
Q4 | $17K | Buy |
154
+66
| +75% | +$8.26K | ﹤0.01% | 2212 |
|
|
2018
Q3 | $12K | Buy |
88
+12
| +16% | +$1.48K | ﹤0.01% | 2733 |
|
|
2018
Q2 | $9K | Buy |
76
+24
| +46% | +$2.6K | ﹤0.01% | 2951 |
|
|
2018
Q1 | $6K | Hold |
52
| – | – | ﹤0.01% | 3058 |
|
|
2017
Q4 | $6K | Sell |
52
-500
| -91% | -$54.4K | ﹤0.01% | 3104 |
|
|
2017
Q3 | $60K | Buy |
552
+48
| +10% | +$4.93K | ﹤0.01% | 1878 |
|
|
2017
Q2 | $51K | Hold |
504
| – | – | ﹤0.01% | 1956 |
|
|
2017
Q1 | $45K | Hold |
504
| – | – | ﹤0.01% | 1990 |
|
|
2016
Q4 | $38K | Hold |
504
| – | – | ﹤0.01% | 2036 |
|
|
2016
Q3 | $42K | Sell |
504
-44
| -8% | -$3.69K | ﹤0.01% | 1918 |
|
|
2016
Q2 | $45K | Buy |
+548
| New | +$45.1K | ﹤0.01% | 1828 |
|
|
2016
Q1 | – | Sell |
-736
| Closed | -$59K | – | 2559 |
|
|
2015
Q4 | $59K | Buy |
+736
| New | +$53.1K | ﹤0.01% | 1504 |
|
Other funds holding CRL
AI
IFP Advisors's CRL Position: Q2 2026 in Review
IFP Advisors reduced its Charles River Laboratories (CRL) stake by 92% in Q2 2026, selling an estimated $126K and leaving 58 shares worth $13.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3227.
IFP Advisors first reported a position in CRL in Q4 2015 and has held it in 40 quarters since. The position peaked at $329K in Q3 2022. 569 funds tracked by Wall St. Rank hold CRL as of Q2 2026.
- IFP Advisors held 58 shares of Charles River Laboratories worth $13.2K as of Q2 2026.
- IFP Advisors sold 710 Charles River Laboratories shares in Q2 2026, an estimated $126K.
- Charles River Laboratories made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #3227 holding.
- IFP Advisors first reported a position in Charles River Laboratories in Q4 2015 and has held it in 40 quarters since.
- IFP Advisors's Charles River Laboratories position peaked at $329K in Q3 2022.
- 569 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.
Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.